Research Article

Resolvin D1 Alleviates Ventilator-Induced Lung Injury in Mice by Activating PPAR γ/NF-κB Signaling Pathway

Haifa Xia,1,2 Jingxu Wang,1,2 Shujun Sun,1,2 Fuquan Wang,1,2 Yiyi Yang,1,2 Lin Chen,1,2 Zhipeng Sun,1,3 and Shanglong Yao1,2

1Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2Department of Anesthesia, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3Department of Anesthesia, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China

Correspondence should be addressed to Zhipeng Sun; sunheizi@163.com and Shanglong Yao; ysltian@163.com

Received 24 February 2019; Revised 22 April 2019; Accepted 15 May 2019; Published 4 June 2019

Academic Editor: Torsten Goldmann

Copyright © 2019 Haifa Xia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As one of the basic treatment modalities in the intensive care unit (ICU), mechanical ventilation can cause or aggravate acute lung injury or ventilator-induced lung injury (VILI). Resolvin D1 (RvD1) is an endogenous polyunsaturated fatty acid derivative with strong anti-inflammatory action. In this study, we explored if RvD1 possesses a protective effect on VILI. Mice were ventilated with high tidal volume (40 mL/kg, HV_T) for 4 h and were then intraperitoneally administered RvD1 at the beginning of high tidal volume ventilation and given GW9662 (a PPAR-γ antagonist) intraperitoneally 30 min before ventilation. RvD1 attenuated VILI, as evidenced by improved oxygenation and reduced histological injury, compared with HV_T-induced lung injury. Similarly, it could ameliorate neutrophil accumulation and production of proinflammatory cytokines in lung tissue. In contrast, the protective effect of RvD1 on lung tissue could be reversed by GW9662. RvD1 mitigated VILI by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) and inhibiting nuclear factor-kappa B (NF-κB) signaling pathways in mice. In conclusion, RvD1 could reduce the inflammatory response in VILI by activating PPAR-γ and inhibiting NF-κB signaling pathways.

1. Introduction

Mechanical ventilation (MV), an essential technology in the intensive care unit (ICU), as a life-saving measure, is extensively applied in patients with pulmonary dysfunction or injury. MV can cause and aggravate lung injury, thereby putting patients at risk of ventilator-induced lung injury (VILI), which can lead to increased morbidity and mortality [1–3], especially when the therapeutic focus is mainly directed at inflammation inhibition, since VILI is characterized by destruction of the alveolar-capillary barrier and increased permeability, resulting in edema, inflammatory leukocyte infiltration (predominantly neutrophils), and bleeding [3, 4]. Specialized proresolving lipid mediators, including the lipoxins, resolvins, protectins, and maresins, were identified by Serhan et al. and they have offered a novel way to resolve inflammation [5–10]. Resolvin D1 (RvD1) was stereochemically assigned as 7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, and 19Z-docosahexaenoic acid [11], and previous studies showed that it possessed effective and stereoselective anti-inflammatory effects, such as limiting neutrophil infiltration and promoting apoptosis [12]. Several studies indicated that RvD1 worked on a number of pulmonary inflammatory conditions, including cystic fibrosis lung disease [13], asthma [14], and ALI (induced by LPS) [15]. RvD1 promotes inflammatory resolving mainly by reducing neutrophil infiltration, inhibiting the interaction between neutrophils and platelets, and enhancing restitution of barrier integrity [15]. In addition, it was found that RvD1 could directly act on the single cell level to prevent neutrophils migration to the endogenous chemokine interleukin-1β as well as enhance the phagocytosis of human macrophages [16, 17]. Meanwhile,
RvD1 reduces endothelium-dependent nitric oxide production, and expression of leukocyte adhesion receptors directly regulates endothelial interactions in vivo. As we all know, aggregation of neutrophils, disruption of alveolar-capillary barrier, and release of proinflammatory factors inflammatory cytokines are all characteristics of inflammation induced by VILI [18]. Therefore, the present study was undertaken to investigate the role of RvD1 associated mechanism in the resolution of VILI. What is more, it has been proved that lipoxins, a kind of proresolving lipid mediators as well as RvD1, exert their anti-inflammatory effects in VILI [19]. Therefore, the question as to whether RvD1 could exert protective effects to alleviate the lung injury induced by ventilation should be answered.

PPARγ, a ligand-activated transcription factor, has effects on type 2 diabetes, atherosclerosis, and cancer [20]. Activation of PPARγ by its ligands also reduces the expression of proinflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin (IL)-1β, and its induction is mediated via NF-κB and mitogen-activated protein kinase [21]. Some studies suggested that lung inflammation induced by LPS might be attenuated by RvD1, and the protective mechanisms might be ascribed to the selective reaction in the NF-κB pathway [22, 23]. Nonetheless, whether RvD1 has a protective effect on VILI and what role PPARγ plays in the inflammatory control of RvD1 have been poorly understood. In this study, we aimed to know if RvD1 exerts its protective effects in VILI by inhibiting NF-κB via activating PPARγ.

2. Materials and Methods

2.1. Animals. 6-8-week-old male C57BL/6 mice (Experimental Animal Center of Wuhan University, China) weighing 20-25 g were kept in the specific pathogen-free environment (12/12 h of the light/dark cycle, 22-24°C), with free access to food and water. Animals were fasted 12 h before experiments but allowed water ad libitum. All animal experiments were approved by the Animal Care and Use Committee of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

2.2. Experimental Design. Mice were weighed and then anesthetized with ketamine (120 mg/kg, intraperitoneally) and xylazine (8 mg/kg, intraperitoneally). One-fourth of the initial dose of anesthetic drugs was supplied about every 1 h to maintain anesthesia during the experimental period. The mice were fixed in a supine position on a heating blanket and were subjected to tracheotomy. A 20G vein catheter was inserted for mechanical ventilation (Model 863 Ventilator; Harvard, USA). Mice in all groups, except the sham group, had 40 ml/kg ventilation and 80 breaths/min for 4 hours as described previously [24] and underwent mechanical ventilation for 0 positive end-expiratory pressure.

As shown in Figure 1, mice were randomly divided into 4 groups (n=7 per group): sham group (sham); high tidal volume group (HV_4); 500 ng RvD1 plus HV_4 group (RvD1); PPAR-γ inhibitor group (GW9662).

RvD1 (Cayman Chemical Company, USA) was diluted with saline as per instructions and then injected intraperitoneally at the beginning of ventilation. The dosage of 500 ng/mouse was selected based on our own preexperimental data and previous studies [25]. Mice subjected to sham and HV_4 group were injected with an identical volume of saline at the same time point. GW9662 (Santa Cruz, USA) was dissolved in 10% DMSO (no effect on mice) according to the instructions and administered a dose of 1 mg/kg intraperitoneally 30 min before the start of mechanical ventilation. Both the time and the dose of administration are based on previous descriptions [26]. All experiments were carried out at least three times with different mice.

2.3. Measurement of PaO2. At the end of the experiment, the arterial blood (heparinized) from the abdominal aorta was analyzed for blood gas, and a blood gas analyzer was employed to measure the level of PaO2 in the blood.

2.4. Histological Analysis. The right lung tissue was fixed in 4% paraformaldehyde for 24 h and embedded with paraffin. Sections of 4 μm thickness were made under an ordinary optical microscope and were HE-stained. The lung injury was
rated on a scoring system developed by American Thoracic Society [27].

2.5. Lung Wet-to-Dry Weight Ratio. The right middle lung was weighed after the surface was cleaned with absorbent paper and then placed in an oven until the weight was constant. The W/D ratio was calculated as a measure of the severity of pulmonary edema.

2.6. Bronchoalveolar Lavage Analysis. Bronchoalveolar lavage was performed using three aliquots of 0.5mL phosphate-buffered saline (PBS) as previously described [19]. After being centrifugated at 12000 rpm at 4°C for 15min, the supernatant was collected and used for total protein concentration by BCA assay kit (Thermo Scientific). The sediment was resuspended in PBS, and the total number of BALF cells was determined by a hematocytometer. Cytospin (Thermo Shandon, Pittsburgh, Pennsylvania) was used to coat another part of the suspension at 800rpm for 10 minutes on a microscope slide. Wright Giemsa was used to stain the sections and count more than 300 cells under an optical microscope for histopathological examination and for differentiation of neutrophils and macrophages.

2.7. Cytokine Analysis in BALF. The concentrations of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, receptor for advanced glycation end-products (RAGE) were determined by enzyme-linked immunosorbent assays (IL-1β, TNF-α, IL-6 from NeoBioscience, Shenzhen, China; RAGE from Ray Bio, USA).

2.8. Protein Extraction and Western Blot. The total protein of lung tissue was isolated with a protein extraction kit (Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer’s protocol. Nuclear and cytoplasmic fractionations were performed using ER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, USA). Protein concentrations were measured with the BCA Protein Assay kit. The samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) in 10% polyacrylamide gels. Immunoblotting was performed with antibodies to NF-κB p65 or IκB or PP AR-γ (Santa Cruz Biotechnology) then using HRP-labeled-goat anti-rabbit antibody. Image Lab was used for quantification.

2.9. Electrophoretic Mobility Shift Assay. The preparation of nuclear extract was carried out as previously described. The oligonucleotide probe corresponding to the consistent sequence of the binding site of ‘5-AGTTGAGGGGACTCC-CAGGC-3’ was synthesized and labeled with biotin. According to the instructions of commercial kits, electrophoretic mobility shift analysis (EMSA) was performed using the LightShift Chemiluminescent EMSA kit (Thermo Scientific, USA).

2.10. Statistical Analysis. All results are expressed as means ± standard errors of the means (SEM) and analyzed using GraphPad Prism (version 6.0, USA). One way ANOVA followed by the least significant difference post hoc test was used to assess differences between groups. A P < 0.05 was considered significant.

3. Results

3.1. RvD1 Attenuated Ventilator-Induced Lung Injury. As shown in Figure 1(a), no significant change was observed in the tissue of the sham-operation group. Conversely, samples from HV T animals were conspicuously damaged, suggesting a significant deterioration in inflammatory cell infiltration, alveolar interstitial edema, airspace, and transparent membranes being filled with protein fragments (Figure 1(b)). The pathological changes of the lung caused by HV T ventilation were not obvious after treatment with RvD1 (Figure 1(c)). However, animals treated with GW9662 exhibited changes similar to those found in the HV T animals (Figure 2(d)) and their lung injury scores were consistent with the pathohistological changes (Figure 2(e)).

3.2. RvD1 Improved Pulmonary Functions in Ventilator-Induced Mice. Lung injury was assessed by such measures as the ratio of lung wet/dry weight and protein levels in BALF and PaO2. Protein levels were used to reflect the microvascular permeability; the degree of pulmonary edema was measured by the lung wet/dry weight ratio; lung oxygenation capacity was evaluated in terms of the level of PaO2. Figures 3(a) and 3(b) show that there was no injury in the sham-operation group, whereas HV T caused severe exudation and edema. The protein level in BALF and the W/D ratio were lowered by RvD1, but this action was partially abolished upon administration of GW9662.

Figure 4(a) shows that HV T, in general, caused significant changes in arterial oxygen partial pressure (PaO2). PaO2 was significantly lowered in HV T group, whereas in the sham-operation group, PaO2 was normal. RvD1, in particular, substantially improved the oxygenation capacity. However, after administration of GW9662, the protective effect was diminished compared with the RvD1 group.

3.3. RvD1 Reduced Ventilator-Induced Neutrophil Infiltration. Figure 4(b) exhibits that the cell counts in BALF were constantly higher in the HV T group than in the sham-operation group. Changes in RvD1-treated mice were different from those in the HV T group, including total lymphocytes and neutrophils. RvD1-treated group reduced the recruitment of inflammatory cells to the lungs. On the contrary, there was no significant difference in the number of macrophages between RvD1-treated group and HV T. Our findings suggested that the increased white blood cells were principally neutrophils, and the RvD1, as a protector, worked also mainly on neutrophils while GW9662 could abolish this effect to some degree.

3.4. RvD1 Attenuated Inflammatory Response in Ventilator-Induced Mice. Compared to the sham-operation group, HV T significantly increased the production of cytokines. RvD1 markedly downregulated the expression of IL-1β (Figure 5(a)), IL-6 (Figure 5(b)), TNF-α (Figure 5(c)), and RAGE.

BioMed Research International
3.5. Effect of RvD1 on PPARγ, IκBα, and NF-κB p65 Subunit Expression in Ventilator-Induced Lung Injury. As shown in (Figures 6(a) and 6(b)), HV T ventilation upregulated the expression of PPARγ and NF-κB p65 subunit. Treatment with RvD1 suppressed ventilation-activated signaling molecules, and the effect was reversed by GW9662. The levels of IκBα were downregulated in response to HV T ventilation compared with the sham-operation group. However, RvD1 treatment inhibited ventilation-induced IκBα degradation, which was partially blocked after GW9662 was given.
3.6. RvD1 Reduced DNA-Binding Activity of NF-κB in Ventilator-Induced Mice. Deoxyribonuclease-binding activities of NF-κB were markedly increased in the HV_τ animals (Figure 7). This change was obviously relieved in the RvD1-treated animals, whereas the NF-κB DNA-binding activity was significantly enhanced upon administration of GW9662.

4. Discussion

Mechanical ventilation (MV) is considered an indispensable supportive treatment for respiratory failure. However, a major concern with mechanical ventilation is VILI, which warrants effective addressing. In this study, the VILI model was successfully established, according to a previously described technique [24]. Our model developed a disrupted alveolar-capillary barrier, which mimicked the pathological changes of VILI (the interstitial edema, increased microvascular permeability, the release of proinflammatory cytokines, and neutrophil infiltration) and had all the signs indicative of its success.

By employing the model, we demonstrated that RvD1 exerted a strong protective effect on acute lung inflammation. Our experimental results revealed that the use of RvD1 could significantly relieve the pathological changes of lungs, pulmonary edema, leukocyte infiltration, and release of proinflammatory mediators. The main pathological changes of lung inflammation involve the disruption of epithelial barrier [28]. Serum breaks through the impaired epithelial cells and infiltrates into lung tissues, resulting in increased protein level in BALF and development of pulmonary edema. Protein in BALF can serve as a measure for pulmonary vascular permeability and is an indicator of acute lung injury [29].
Figure 5: RvD1 reduced the production of inflammatory cytokines. IL-1β (a), IL-6 (b), TNF-α (c), RAGE (d). Data are presented as means ± SEM, n = 7. ** means P < 0.01 versus sham group; ## P < 0.01 versus HV group; && P < 0.01 versus RvD1 group.

Figure 6: RvD1 affects the expression of IκBα, NF-κB p65 subunit, and PPARγ in VILI mice. Western blot analysis for PPARγ (a), IκBα (b), and NF-κB p65 (c). PPARγ protein levels normalized by GADPH (d), IκBα protein levels normalized by GADPH (e), NF-κB p65 protein levels normalized by GADPH (f). Data are presented as means ± SEM, n = 7. ** means P < 0.01 versus sham group; ## P < 0.01 versus HV group; && P < 0.01 versus RvD1 group.
In this study, RvD1 could reduce protein concentration in the BALF, suggesting that RvD1 can effectively protect pulmonary vascular endothelial and thereby maintain the vascular permeability in VILI-induced inflammation. Since edema reflects the severity of inflammation [30], we used W/D ratios as a measure for the degree of edema. Our results showed that RvD1 could significantly inhibit VILI-induced pulmonary edema, suggesting that RvD1 possesses a powerful antiedematogenic effect.

High tidal volume ventilation has been found to elevate the plasma cytokine level [31, 32], and the increased proinflammatory cytokines, such as factor TNF-α, and interleukins (IL-1β, IL-6) [27, 28], believed to be the markers of inflammation, are associated with an unfavorable prognosis in patients with VILI [33]. Our results exhibited that RvD1 evidently decreased the levels of IL-1β, TNF-α, IL-6 in BALF of HV/T animals and the findings were coincident with previous results [34]. RAGE is highly expressed in the lungs, primarily on the basolateral membrane of alveolar type I cells [31], and several studies demonstrated that RAGE could be used as a biomarker for lung injury both in animal models and in clinical practice [32, 35]. Further study showed that RAGE signaling was conducive to the proinflammatory status or process in ventilator-induced lung injury [36]. Our study showed that treatment with RvD1 lowered the expression of RAGE and that RvD1 could reduce proinflammatory factors of the early phase of inflammation, especially in VILI.

The neutrophil infiltration plays an essential role in proinflammatory processes in VILI [37]. The main histological feature in resolution is the loss of neutrophils from the local inflamed sites. [38]. Our results showed that after treatment with RvD1, fewer neutrophils infiltrated into the alveolar space, as evidenced by histological analysis of lung tissue and the cell counts in BALF. RvD1 may restrict total leukocytic infiltration through the same mechanisms by which RvD1 not only reduces inflammation but also promotes resolution back to noninflammatory state [38]. At the tissue level, several mechanisms might be at work.

(1) It might reduce the levels of proinflammatory mediators, just like prostaglandins [39]; (2) it might prevent neutrophils from entering the inflamed area; (3) the production of nitric oxide stimulated by endothelial cells might block the adhesion of leukocytes to vascular endothelial cells and stimulate macrophages to phagocytize apoptotic neutrophils [38]; the orphan receptor G-protein-coupled receptor 32 (GPR32) and the lipoxin A4/Annexin-A1 receptor formyl-peptide receptor 2 (FPR2/ALX) were reported as mediators in the process of RvD1 regulated human neutrophil recruitment [39]. GPR32 and FPR2/ALX are expressed on human cells which are directly related to inflammation, including neutrophils, lymphocytes, macrophages, and monocytes [40]. It is generally believed that RvD1 binds to GPR32 during periods of homeostasis, while RvD1 interacts with ALX/FPR2 during periods of resolving inflammation. Recently, studies show that RvD1 could promote the transformation of macrophage phenotype from proinflammatory to a proresolving M2-like phenotype by triggering both GPR32 and FPR2/ALX [41]. GPR32 and ALX/FPR2 receptors engaged RvD1 to inhibit the secretion of cytokines by CD8 T cells, and CD4 T cells indicate that RvD1 exerts its anti-inflammatory effects through binding to these two receptors. As a promiscuous G-protein coupled receptor (GPCR), FPR2/ALX participates in promoting the resolution of inflammation, such as neutrophil extravasation limitation, neutrophil apoptosis induction, and apoptotic cell phagocytosis promotion acts in the monocyte recruitment modulation.

PPARγ is involved in the lipid metabolism, cell differentiation, and, more importantly, inflammatory processes, including cytokine production and antigen presentation [42]. Previous studies have suggested that the PPARγ pathway plays a vital role in developing multiform of damage shown in VILI [43]. After toll-like receptors (TLRs) recognize the antigen, they activate the NF-κB pathway to regulate the expression of cytokines and other proteins with antimicrobial activity or signaling properties [44]. Multiple steps in the NF-κB signaling pathway could be inhibited by PPARγ ligands, and once activated, they lead to the inhibition of NF-κB [45]. GW9662, a potent irreversible and selective antagonist of PPARγ, is known to be a useful tool for studying the role of PPARγ in biological processes [46]. In our study, we found that treatment with GW9662 could partially reduce the inhibition of NF-κB activation induced by RvD1, indicating that RvD1 attenuated VILI possibly through PPARγ/NF-κB pathway. All of these findings indicated that the inflammation resolution induced by RvD1 might depend on the NF-κB signaling pathways.

5. Conclusions

Our results indicated that RvD1 could limit lung inflammation in VILI mice and suppress the NF-κB p-65 subunit. We also demonstrated that the inhibition of NF-κB activation might, to some degree, be partially reduced through PPARγ. On the basis of the results, we are led to conclude that RvD1 can reduce the inflammatory response in VILI by activating PPAR-γ and inhibiting NF-κB signaling pathways.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Haifa Xia and Jingxu Wang contributed equally to designing the study, carrying out experiments, collecting and analyzing data, and writing the manuscript. These authors can vouch for the integrity of the data analysis. Yiyi Yang and Fuquan Wang carried out the Western blot analysis and contributed to data collection. Shujun Sun and Lin Chen contributed to data collection. Zhipeng Sun and Shanglong Yao contributed to the design of the experiments and revised the article. All authors read and approved the final manuscript. Haifa Xia and Jingxu Wang made an equal contribution to this work.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81701887; No. 81671890) and the Natural Science Foundation of Hubei Province (2018CFC856).

References

[1] L. N. Tremblay and A. S. Slutsky, "Ventilator-induced lung injury: From the bench to the bedside," Intensive Care Medicine, vol. 32, no. 1, pp. 24–33, 2006.

[2] C. C. Dos Santos, Y. Shan, A. Akram et al., "Neuroimmune regulation of ventilator-induced lung injury," American Journal of Respiratory & Critical Care Medicine, vol. 183, no. 4, pp. 471-82, 2011.

[3] J. A. Belperio, M. P. Keane, M. D. Burdick et al., "Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury," The Journal of Clinical Investigation, vol. 110, no. 11, pp. 1703–1716, 2002.

[4] L. Li, C. Shen, and E. Nakamura, "SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer," Cancer Cell, vol. 24, no. 6, pp. 738–750, 2013.

[5] C. N. Serhan, M. Hamberg, and B. Samuelsson, "Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes," Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 17, pp. 5333–5339, 1984.

[6] C. N. Serhan, C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert, "Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing," The Journal of Experimental Medicine, vol. 192, no. 8, pp. 1197–1204, 2000.

[7] C. N. Serhan, "Controlling the resolution of acute inflammation: A new genus of dual anti-inflammatory and proresolving mediators," Journal of Periodontology, vol. 79, no. 8, pp. 1520–1526, 2008.

[8] C. N. Serhan and N. Chiang, "Resolution phase lipid mediators of inflammation: agonists of resolution," Current Opinion in Pharmacology, vol. 13, no. 4, pp. 632–640, 2013.

[9] C. N. Serhan, "Pro-resolving lipid mediators are leads for resolution physiology," Nature, vol. 510, no. 7503, pp. 92–101, 2014.

[10] H. Xia, L. Chen, H. Liu et al., "Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype," Scientific Reports, vol. 7, no. 1, pp. 99 pages, 2017.

[11] Y. Sun, S. F. Oh, J. Uddin et al., "Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation," The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9323–9334, 2007.

[12] W. Yaxin, Y. Shanglong, S. Huaqing et al., "Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12/CXCR4 pathway," Journal of Surgical Research, vol. 188, no. 1, pp. 213–221, 2014.

[13] F. C. Ringholz, G. Higgins, A. Hatton et al., "Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways," Journal of Cystic Fibrosis, vol. 17, no. 5, pp. 607–615, 2018.

[14] A. P. Rogerio, O. Haworth, R. Croze et al., "Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses," The Journal of Immunology, vol. 189, no. 4, pp. 1983–1991, 2012.

[15] O. Eickmeier, H. Seki, O. Haworth et al., "Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury," Mucosal Immunology, vol. 6, no. 2, pp. 256–266, 2013.

[16] A. J. Merched, K. Ko, K. H. Gotlinger, C. N. Serhan, and L. Chan, "Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators," The FASEB Journal, vol. 22, no. 10, pp. 3595–3606, 2008.

[17] K. Kasuga, R. Yang, and T. F. Porter, "Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution," The Journal of Immunology, vol. 181, no. 12, pp. 8677–8687, 2008.

[18] J. A. Frank and M. A. Matthay, "Science review: mechanisms of ventilator-induced lung injury," Critical Care, vol. 7, no. 3, pp. 233–241, 2003.

[19] H. Li, Z. Wu, D. Feng et al., "BML-111, a lipoxin receptor agonist, attenuates ventilator-induced lung injury in rats," Shock, vol. 41, no. 4, pp. 311–316, 2014.

[20] E. D. Rosen and B. M. Spiegelman, "PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth," The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001.

[21] K. Harada, K. Isse, T. Kamihira, S. Shimoda, and Y. Nakanuma, "Th1 cytokine-induced downregulation of PPARγ in human biliary cells relates to cholangitis in primary biliary cirrhosis," Hepatology, vol. 41, no. 6, pp. 1329–1338, 2005.

[22] Z. Liao, J. Dong, and W. Wu, "Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway," Respiratory Research, vol. 13, no. 1, article 110, pp. 1–11, 2012.

[23] B. Wang, X. Gong, J.-y. Wan et al., "Resolvin D1 protects mice from LPS-induced acute lung injury," Pulmonary Pharmacology & Therapeutics, vol. 24, no. 4, pp. 434–441, 2011.

[24] S. Tao, M. Rojo de la Vega, H. Quijada et al., "Bixin protects mice against ventilation-induced lung injury in an NRF2-dependent manner," Scientific Reports, vol. 6, no. 1, Article ID 18760, 2016.
in the resolution of lung inflammation,” Molecular Aspects of Medicine, vol. 58, pp. 44–56, 2017.

[41] M. Schmid, C. Gemperle, N. Rimann, and M. Hersberger, “Resolvin D1 polarizes primary human macrophages toward a proresolution phenotype through GPR32,” The Journal of Immunology, vol. 196, no. 8, Article ID 1501701, pp. 3429–3437, 2016.

[42] M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 19, no. 5, pp. 557–566, 2013.

[43] A. Hoetzel, T. Dolinay, S. Vallbracht et al., “Carbon monoxide protects against ventilator-induced lung injury via PPAR-γ and inhibition of Egr-1,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 11, pp. 1223–1232, 2008.

[44] S. Lajos, T. R. C. Daniel, and László, “PPARgamma in immunity and inflammation: cell types and diseases,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1004–1030, 2007.

[45] A. Klopotek, F. Hirche, and K. Eder, “PPARγ ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2,” Experimental Biology and Medicine, vol. 231, no. 8, pp. 1365–1372, 2006.

[46] L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002.

[25] Z. Liao, J. Dong, and W. Wu, “Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway,” Respiratory Research, vol. 13, no. 1, article 110, 2012.

[26] M. Collin, M. Abdelrahman, and C. Thiemermann, “Endogenous ligands of PPAR-γ reduce the liver injury in haemorrhagic shock,” European Journal of Pharmacology, vol. 486, no. 2, pp. 233–235, 2004.

[27] M. B. Gustavo, G. Downey, B. B. Moore et al., “An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals,” American Journal of Respiratory Cell Molecular Biology, vol. 44, no. 5, pp. 725–738, 2011.

[28] M. Shirasawa, N. Fujiwara, S. Hirabayashi et al., “Receptor for advanced glycation end-products is a marker of type I lung alveolar cells,” Genes to Cells, vol. 9, no. 2, pp. 165–174, 2004.

[29] X. Su, M. R. Looney, N. Gupta, and M. A. Mathay, “Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 297, no. 1, pp. L1–L5, 2009.

[30] J. Kou, Y. Sun, Y. Lin et al., “Anti-inflammatory activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents,” Biological & Pharmaceutical Bulletin, vol. 28, no. 7, pp. 1234–1238, 2005.

[31] M. Shirasawa, N. Matsuura, M. Nishimura, N. Ohira, and H. Kiyono, “Ventilator-induced lung injury is associated with neutrophil infiltration, macrophage activation, and TGF-β1 mRNA upregulation in rat lungs,” Anesthesia & Analgesia, vol. 92, no. 2, pp. 428–436, 2001.

[32] C. N. Serhan, N. Chiang, and T. E. Van Dyke, “Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators,” Nature Reviews Immunology, vol. 8, no. 5, pp. 349–361, 2008.

[33] L. V. Norling, J. Dalli, R. J. Flower, C. N. Serhan, and M. Perretti, “Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 8, pp. 1970–1978, 2012.

[34] M. G. Duvall, T. R. Bruggemann, and B. D. Levy, “Bronchoprotective mechanisms for specialized pro-resolving mediators for clinical trials,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1004–1030, 2007.

[35] A. Klopotek, F. Hirche, and K. Eder, “PPARγ ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2,” Experimental Biology and Medicine, vol. 231, no. 8, pp. 1365–1372, 2006.

[36] L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002.